CDK6抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cell lysate, Primary antibody: P07183(CDK6 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P07183(CDK6 Antibody) at dilution 1/80. (Original magnification: ×200)    

  
  

The cyclin-dependent kinase 6 (CDK6) is a member of the CDK family, which regulates cell cycle progression by forming complexes with cyclins. CDK6. along with CDK4. drives the transition from the G1 to S phase by phosphorylating retinoblastoma (Rb) protein, releasing E2F transcription factors to promote DNA replication. Dysregulation of CDK6 is implicated in various cancers, including leukemias, lymphomas, and solid tumors, due to its role in cell proliferation and survival. Overexpression, gene amplification, or mutations in CDK6 can lead to uncontrolled cell division, making it a therapeutic target.

CDK6 antibodies are essential tools for studying its expression, localization, and interactions in both normal and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess CDK6 levels in cancer tissues, aiding in prognosis evaluation or biomarker identification. In drug development, CDK6-specific antibodies help validate target engagement of inhibitors (e.g., palbociclib, ribociclib) and monitor therapeutic responses. Additionally, isoform-selective antibodies distinguish CDK6 from its homolog CDK4. which shares functional overlap but may have distinct roles in certain cancers or resistance mechanisms. Recent research also explores CDK6's non-canonical functions in transcriptional regulation and angiogenesis, expanding its relevance beyond cell cycle control. As CDK6-targeted therapies advance, reliable antibodies remain critical for mechanistic studies and clinical applications.